Fig. 4From: Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patientsProtein expression profiles and prognostic values of LanCL2 and EGFR in GBM samples of tumor banks. A Frequencies of LanCL2 and EGFR protein overexpression in GBM samples of our tumor banks. B, C Relative expression of LanCL2 and EGFR in GBM samples was evaluated by measurement of density of immunoblotting bands. P values were determined by Mann–Whitney U test. ***p < 0.001. D, E Relative expression of LanCL2 and EGFR in newly diagnosed and relapsing GBM samples. Grade I gliomas were used for comparison, and GAPDH was served as the endogenous control. P values were determined by Kruskal–Wallis One-Way ANOVA and Dunn’s multiple comparisons. *p < 0.05; **p < 0.01. F Representative immunoblots of LanCL2 and EGFR protein expression in newly diagnosed and relapsing GBM specimens. G Person’s correlation analysis showed that protein expression of LanCL2 and EGFR was not significantly correlated. H Chi-square test showed the correlations between the protein expression of LanCL2 & EGFR and IDH1/2 mutation, MGMT methylation and TERT promoter mutation. I, J Protein overexpression of LanCL2 and EGFR was not significantly correlated with OS of GBM patientsBack to article page